Literature DB >> 24369815

Prescribing selective serotonin reuptake inhibitors in older age.

Anya Topiwala1, Leonidas Chouliaras1, Klaus P Ebmeier2.   

Abstract

Apart from commercial reasons, two motivations have led to the introduction of SSRIs to replace the first and second generation antidepressants already available. One was the search for a more rational treatment, based on specific mechanisms, the other the development of effective treatments with fewer side effects, particularly for older patients, who have a greater sensitivity to cardio-vascular and central nervous system effects. The first has been frustrated up to a point, in that SSRIs and other single mechanism drugs do not appear to be more effective than the earliest relatively non-specific antidepressants. The second has been fulfilled, in that SSRIs generally are better tolerated in older patients and in overdose. However, there is a spectrum of other side effects that are particularly relevant in older age and that need attention when treating depression in this particular patient group.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antidepressants; CGI; CI; CYP219; Clinical Global Impression (scale); Cytochrome P450 2C19; EPSE; FDA; HAM-D; Hamilton Depression Rating scale; MADRS; MHRA; Major depressive disorder; Medicines and Healthcare products Regulatory Agency; Montgomery-Åsberg Depression Rating scale; NNT; OR; PPIs; QT interval corrected (for heart rate); QTc; RCT; RR; Randomized controlled trials; Risks; SNRI (s); SSRI(s); Side effects; Suicide; TCA(s); US Food and Drug Administration; confidence interval; extrapyramidal side effects; numbers needed to treat; odds ratio; proton pump inhibitors; randomized controlled trial; risk ratio; serotonin reuptake inhibitor(s); serotonin–norepinephrine reuptake inhibitor(s); tricyclic antidepressants(s)

Mesh:

Substances:

Year:  2013        PMID: 24369815     DOI: 10.1016/j.maturitas.2013.11.006

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

Review 1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.

Authors:  Glenda M MacQueen; Benicio N Frey; Zahinoor Ismail; Natalia Jaworska; Meir Steiner; Ryan J Van Lieshout; Sidney H Kennedy; Raymond W Lam; Roumen V Milev; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 2.  Antidepressant pharmacotherapy in old-age depression-a review and clinical approach.

Authors:  Nathalie Pruckner; Vjera Holthoff-Detto
Journal:  Eur J Clin Pharmacol       Date:  2017-03-10       Impact factor: 2.953

3.  Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort.

Authors:  I Carrière; A Farré; J Norton; M Wyart; C Tzourio; P Noize; K Pérès; A Fourrier-Réglat; M L Ancelin
Journal:  Osteoporos Int       Date:  2016-06-16       Impact factor: 4.507

4.  Selective serotonin reuptake inhibitor use in hip fracture patients: a Danish nationwide prevalence study.

Authors:  Stine B Bruun; Irene Petersen; Nickolaj R Kristensen; Deirdre Cronin-Fenton; Alma B Pedersen
Journal:  Acta Orthop       Date:  2018-12-10       Impact factor: 3.717

5.  Serotonin syndrome induced by the readministration of escitalopram after a short-term interruption in an elderly woman with depression: a case report.

Authors:  Yasushi Sato; Kazuhiko Nakamura; Norio Yasui-Furukori
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-30       Impact factor: 2.570

6.  In Vitro Activity of Sertraline, an Antidepressant, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains.

Authors:  Paweł Krzyżek; Roman Franiczek; Barbara Krzyżanowska; Łukasz Łaczmański; Paweł Migdał; Grażyna Gościniak
Journal:  Pathogens       Date:  2019-11-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.